The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease. - Wikidata - wikimedia - TriplyDB

The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.

The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.

http://www.wikidata.org/entity/Q37840099

about

Mice lacking the intestinal peptide transporter display reduced energy intake and a subtle maldigestion/malabsorption that protects them from diet-induced obesity.Emerging treatment options for short bowel syndrome: potential role of teduglutide Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes.Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity.Review article: a comparison of glucagon-like peptides 1 and 2.Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus.Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy

P2860

Q34620747-E590CE43-B282-4791-A7C2-BF3006689B03 Q35304614-D2A0166D-3E86-4106-B6E0-D2C7D5A30B9F Q35373283-182DF539-0EE1-4D81-8974-02801942536E Q35971449-C156AD1D-C656-42FD-B0B3-8186A551F5AA Q38057350-498B5CB5-7AFB-4E03-A45C-4285901A3E80 Q40345569-812D063E-284A-4345-97FC-70C142A3235D Q56771767-9C6B850F-C962-407E-B4C0-8EB401AE1EFB

P2860

The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.

http://www.wikidata.org/entity/Q37840099

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The therapeutic potential of t ...... r in gastrointestinal disease.

@en

The therapeutic potential of t ...... r in gastrointestinal disease.

@nl

type

label

The therapeutic potential of t ...... r in gastrointestinal disease.

@en

The therapeutic potential of t ...... r in gastrointestinal disease.

@nl

prefLabel

The therapeutic potential of t ...... r in gastrointestinal disease.

@en

The therapeutic potential of t ...... r in gastrointestinal disease.

@nl

P1433

Q37840099-E1B5CD27-1F24-4CF7-9713-BF03F1A2277C

P1476

Q37840099-F2A19408-A42D-4B27-A0CB-3DA6787C69D2

P2093

Q37840099-C34D1291-4061-4CAA-9FA0-97ED707A14EB

Q37840099-FF79D315-C497-42DD-88BC-008C504E7345

P2860

Q37840099-01B057ED-811F-4BEB-A3FE-D1CADFF2BCEC

Q37840099-04BFDB64-6B5C-4DB0-8B9B-F12FADAE093C

Q37840099-099C2158-6EAA-4C75-A7D4-5B06A6D9C604

Q37840099-09A7DA9A-8E95-4889-8B41-02D8AE9EF0D5

Q37840099-0A8D129B-89DA-48F7-9AEA-6201995A1AB5

Q37840099-1BD93609-7980-46D9-AD65-187DD992641C

Q37840099-1C7FB4AF-7938-408E-AAE4-55A2383F3D5C

Q37840099-1E3A051E-C5D4-40AB-AB67-1D5707D60C61

Q37840099-203F4183-0FC4-4140-A784-41085BBA7232

Q37840099-20FF93B7-0FE2-4942-AE97-AADD9CF528A0

P304

Q37840099-5EF68F3C-4674-4DDE-B078-857AB8767268

P31

Q37840099-D072EA19-5FAC-4CD2-9A80-A51AD9293390

P356

Q37840099-FD738648-112E-4075-969B-97A3022DDA36

P407

Q37840099-BCF4DC51-01FE-4740-93E6-5B84D3996D22

P433

Q37840099-53877553-B919-4E04-9E5E-7D939BE7A68D

P478

Q37840099-A1704E23-8A06-4908-AED1-32B42B0A7CBC

P577

Q37840099-9550354D-F391-4E11-AA9C-4CA82291AE8B

P5875

Q37840099-7CA9C5AF-64AB-41F2-80D2-81848D20494D

P698

Q37840099-A5FFA2D1-3D28-4DB1-907B-06C0F81E2331

P356

14728222.2011.556620

P1433

Expert Opinion on Therapeutic Targets

P1476

The therapeutic potential of t ...... r in gastrointestinal disease.

@en

P2093

Beverley A Moore

http://www.w3.org/2001/XMLSchema#string

Pamela J Hornby

http://www.w3.org/2001/XMLSchema#string

P2860

Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2

Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis

Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability

The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways.

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow.

Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors.

Enteroendocrine localization of GLP-2 receptor expression in humans and rodents.

Modulation of specific intestinal epithelial progenitors by enteric neurons.

P304

637-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2011.556620

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49829454

http://www.w3.org/2001/XMLSchema#string

P698

21314232

http://www.w3.org/2001/XMLSchema#string